Cell-penetrating-peptide-mediated siRNA lung delivery.

Sterghios Moschos, Andrew Evan Williams, Mark Lindsay

Research output: Contribution to journalArticlepeer-review

50 Citations (Scopus)

Abstract

The therapeutic application of siRNA (short interfering RNA) shows promise as an alternative approach to small-molecule inhibitors for the treatment of human disease. However, the major obstacle to its use has been the difficulty in delivering these large anionic molecules in vivo. A potential approach to solving this problem is the chemical conjugation of siRNA to the cationic CPPs (cell-penetrating peptides), Tat-(48-60) (transactivator of transcription) and penetratin, which have been shown previously to mediate protein and peptide delivery in a host of animal models. In this transaction, we review recent studies on the utility of siRNA for the investigation of protein function in the airways/lung. We show that, despite previous studies showing the utility of cationic CPPs in vitro, conjugation of siRNA to Tat-(48-60) and penetratin failed to increase residual siRNA-mediated knockdown of p38 MAPK (mitogen-activated protein kinase) (MAPK14) mRNA in mouse lung in vivo. Significantly, we will also discuss potential non-specific actions and the induction of immunological responses by CPPs and their conjugates and how this might limit their application for siRNA-mediated delivery in vivo.
Original languageEnglish
Pages (from-to)807-810
JournalBiochemical Society Transactions
Volume35
Issue number4
DOIs
Publication statusPublished - 1 Aug 2007

Fingerprint Dive into the research topics of 'Cell-penetrating-peptide-mediated siRNA lung delivery.'. Together they form a unique fingerprint.

Cite this